This is a working overview of metabolic research, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-12-18 and is reviewed periodically as new material appears.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
| Property | Value | Notes |
|---|---|---|
| Common synonym | hGH fragment 176-191 | Refers to the C-terminal segment |
| Appearance | White to off-white powder | Typically supplied lyophilized |
| Solubility | Soluble in water and aqueous buffers | Confirm with technical data |
| Typical storage temperature | -20 °C for dry powder | Protect from moisture and light |
| Common analytical method | RP-HPLC with UV detection | Often paired with mass spectrometry |
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
== Function == Elastin, a protein in the extracellular matrix, provides elasticity and its soluble precursor is tropoelastin. When elastin cross links it produces desmosine and isodesmosine. When desmosine is mentioned, it is usually grouped with isodesmosine, the other tetrafunctional amino acid that is specific to elastin.
I would guess if we had gone in there, we would still have forces in Baghdad today. We'd be running the country. We would not have been able to get everybody out and bring everybody home. And the final point that I think needs to be made is this question of casualties. I don't think you could have done all of that without significant additional US casualties, and while everybody was tremendously impressed with the low cost of the conflict, for the 146 Americans who were killed in action and for their families, it wasn't a cheap war.
== Applications == Enteropeptidase's specificity makes it an ideal tool in biochemical applications; a fusion protein containing a C-terminal affinity tag (such as poly-His) linked by this sequence can be cleaved by enteropeptidase to obtain the target protein following protein purification. On the converse, the N-terminal pro-sequence of proteases that must be cleaved prior to activation can be mutated to enable activation with enteropeptidase.
== History == In the first half of the 20th century, Turner and Winks discovered that borosilicate glasses can be leached by acids. Their investigations showed that not only the chemical stability can be influenced by thermal treatment but also density, refractive index, thermal expansion and viscosity. In 1934, Nordberg and Hood discovered that alkali borosilicate glasses separate in soluble (sodium borate rich) and insoluble (silica rich) phases if the glass is thermally treated. By extraction using mineral acids the soluble phase can be removed and a porous silica network remains. During a sintering process after extraction, a silica glass is generated, which has properties approaching those of quartz glass. The manufacturing of such high-silica glasses has been published as the VYCOR-process.
[PtCl4]2- + 2 H2NCH(R)CO2− → [Pt(H2NCH(R)CO2)2] + 4 Cl− Relevant to bioinorganic chemistry, amino acid complexes can be generated by the hydrolysis of amino acid esters and amides (en = ethylenediamine):
Sources: en.wikipedia.org
Therefore, while the electronic placement of hydrogen in group 1 predominates, some rarer arrangements show either hydrogen in group 17, duplicate hydrogen in both groups 1 and 17, or float it separately from all groups. This last option has nonetheless been criticized by the chemist and philosopher of science Eric Scerri on the grounds that it appears to imply that hydrogen is above the periodic law altogether, unlike all the other elements. Helium is the only element that routinely occupies a position in the periodic table that is not consistent with its electronic structure. It has two electrons in its outermost shell, whereas the other noble gases have eight; and it is an s-block element, whereas all other noble gases are p-block elements. However it is unreactive at standard conditions, and has a full outer shell: these properties are like the noble gases in group 18, but not at all like the reactive alkaline earth metals of group 2. For these reasons helium is nearly universally placed in group 18 which its properties best match; a proposal to move helium to group 2 was rejected by IUPAC in 1988 for these reasons. Nonetheless, helium is still occasionally placed in group 2 today, and some of its physical and chemical properties are closer to the group 2 elements and support the electronic placement. Solid helium crystallises in a hexagonal close-packed structure, which matches beryllium and magnesium in group 2, but not the other noble gases in group 18.
=== Mental health and Dementia === Mental health conditions are common in people living with dementia. Depression and anxiety frequently occur alongside cognitive decline, and can worsen day‑to‑day functioning and quality of life. People with dementia who experience co‑morbid depression or anxiety are at increased risk of suicidal ideation, suicide attempts, and death by suicide, particularly in the earlier stages of dementia. Some groups appear to have an even higher likelihood of developing mood problems. For example, frontotemporal dementia is often associated with early behavioural and emotional changes, and people with young‑onset dementia (where symptoms begin before age 65) may be more vulnerable to depression and anxiety because of the impact on employment, identity, and family roles. Mental health conditions in people living with dementia are often under-recognised and undertreated. Untreated depression and anxiety can contribute to distress, behavioural changes, greater care needs and an increased risk of admission to long‑term care. However, it is not inevitable that people with dementia will experience mood problems. When symptoms occur, they can be assessed as for those living without dementia. Non‑drug approaches—such as psychological therapies, social engagement, and activity‑based interventions are recommended as first‑line treatments, with medication reserved for specific situations. Research also suggests that mental health difficulties earlier in life may be linked to later dementia risk.
Australian Rules footballer Daniel Chick elected to have his left ring finger amputated as chronic pain and injury was limiting his performance. Rugby union player Jone Tawake also had a finger removed. National Football League safety Ronnie Lott had the tip of his little finger removed after it was damaged in the 1985 NFL season.
electron transport in the mitochondrial ETC, by shuttling electrons from mitochondrial complexes like nicotinamide adenine dinucleotide (NADH), ubiquinone reductase (complex I), and succinate ubiquinone reductase (complex II), the fatty acids and branched-chain amino acids oxidation (through flavin-linked dehydrogenases) to ubiquinol–cytochrome-c reductase (complex III) of the ETC: CoQ10 participates in fatty acid and glucose metabolism by transferring electrons generated from the reduction of fatty acids and glucose to electron acceptors; antioxidant activity as a lipid-soluble antioxidant together with vitamin E, scavenging reactive oxygen species and protecting cells against oxidative stress, inhibiting the oxidation of proteins, DNA, and use of vitamin E.
== Interactions == The substance is metabolised by the liver enzyme CYP3A4. In a study, the strong CYP3A4 inhibitor ketoconazole increased the maximal blood plasma concentrations of lercanidipine by a factor of eight, and the area under the curve by a factor of 15. In another study, ciclosporin increased lercanidipine plasma levels threefold when given at the same time. Other inhibitors of this enzyme, such as itraconazole, erythromycin, and grapefruit juice, are also expected to increase plasma concentrations and thus amplify the antihypertensive effect. Conversely, CYP3A4 inductors such as carbamazepine, rifampicin, and St John's wort probably lower plasma levels and effectiveness of lercanidipine. By comparison, amlodipine has a lower potential for CYP3A4 mediated interactions. Lercanidipine increases plasma levels of ciclosporin and digoxin.
Sources: en.wikipedia.org
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.
No. It is a shortened peptide fragment, not the full hormone. It does not contain the entire hGH sequence and is studied for different proposed effects.
Regulatory approvals for weight loss are not established in major jurisdictions. Some human trials reported modest changes, but the evidence is limited, and it remains a research compound.
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.